JAK3 and peripheral T-cell lymphoma, not otherwise specified: The efficacy of ruxolitinib, a JAK3-STAT pathway inhibitor, in peripheral T-cell lymphoma patients has been confirmed (66), while a clinical trial evaluating ruxolitinib in ENKTL patients is ongoing (NCT02974647) (6).